Geert J L H Van Leenders

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8223245/publications.pdf

Version: 2024-02-01

102	3,719	136740	143772
papers	citations	32	57
		h-index	g-index

103	103	103	5676
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth. Annals of Diagnostic Pathology, 2022, 56, 151842.	0.6	3
2	Antiâ€“PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. Clinical Cancer Research, 2022, 28, 215-226.	3.2	5
3	Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. Histopathology, 2022, 80, 558-565.	1.6	11
4	Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy. European Urology Open Science, 2022, 36, 19-22.	0.2	1
5	Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach. Journal of Digital Imaging, 2022, 35, 127-136.	1.6	14
6	Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1149-1157.	1.4	2
7	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22
8	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. Bladder Cancer, 2022, , 1-17.	0.2	2
9	Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology, 2022, 80, 1041-1049.	1.6	8
10	<scp>NeuroSAFE</scp> in radical prostatectomy increases the rate of nerveâ€sparing surgery without affecting oncological outcome. BJU International, 2022, 130, 628-636.	1.3	11
11	Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology, 2022, 168, 156-164.	0.5	1
12	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. OncoImmunology, 2022, 11, .	2.1	3
13	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Modern Pathology, 2021, 34, 184-193.	2.9	32
14	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer, 2021, 148, 981-987.	2.3	12
15	Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 249-256.	1.4	22
16	The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading. European Urology, 2021, 79, 707-709.	0.9	13
17	Eight Endorsements of the International Society of Urological Pathology from the 2019 Consensus Conference on Grading of Prostatic Carcinoma. Journal of Urology, 2021, 205, 8-10.	0.2	0
18	GRPr Antagonist ⁶⁸Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-NaÃ¯ve Patients. Journal of Nuclear Medicine, 2021, 62, 1517-1523.	2.8	17

#	Article	IF	Citations
19	PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 705-713.	1.4	1
20	Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. Modern Pathology, 2021, 34, 2064-2070.	2.9	10
21	Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. American Journal of Clinical Pathology, 2021, 156, 895-905.	0.4	5
22	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	0.6	9
23	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1007-1007.	2.1	14
24	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNAâ€“minus RNA sequencing data. GigaScience, 2021, 10, .	3.3	10
25	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. European Urology, 2020, 77, 191-198.	0.9	57
26	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. American Journal of Surgical Pathology, 2020, 44, 191-197.	2.1	20
27	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2020, 44, e87-e99.	2.1	292
28	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	0.9	57
29	Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. Histopathology, 2020, 77, 850-861.	1.6	24
30	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. Genomics, Proteomics and Bioinformatics, 2020, 18, 104-119.	3.0	51
31	Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. European Journal of Radiology, 2020, 131, 109266.	1.2	11
32	Automated detection of cribriform growth patterns in prostate histology images. Scientific Reports, 2020, 10, 14904.	1.6	16
33	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. Journal of Personalized Medicine, 2020, 10, 270.	1.1	7
34	Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2020, 77, 742-748.	1.6	16
35	Intraoperative assessment and reporting of radical prostatectomy specimens to guide nerveâ€sparing surgery in prostate cancer patients (NeuroSAFE). Histopathology, 2020, 77, 539-547.	1.6	15
36	Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Modern Pathology, 2020, 33, 1618-1625.	2.9	11

#	Article	IF	Citations
37	MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma. PLoS ONE, 2020, 15, e0228014.	1.1	3
38	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. Histopathology, 2020, 76, 755-762.	1.6	18
39	Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?. BJU International, 2020, 126, 124-132.	1.3	30
40	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	0.9	151
41	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	1.6	7
42	Relocation of inadequate resection margins in the wound bed during oral cavity oncological surgery: A feasibility study. Head and Neck, 2019, 41, 2159-2166.	0.9	24
43	Differential tissue expression of extracellular vesicleâ€derived proteins in prostate cancer. Prostate, 2019, 79, 1032-1042.	1.2	10
44	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology, 2019, 75, 338-345.	1.6	22
45	Threeâ€dimensional architecture of common benign and precancerous prostate epithelial lesions. Histopathology, 2019, 74, 1036-1044.	1.6	11
46	Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538â€“40. European Urology, 2019, 75, e160-e161.	0.9	0
47	Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Modern Pathology, 2019, 32, 1032-1041.	2.9	30
48	PD-L1 testing in urothelial carcinoma: are we there yet?. Translational Andrology and Urology, 2019, 8, S466-S468.	0.6	0
49	Unique Case of a Rare Mesenchymal Tumor Harboring a Somatic c.119delC VHL Mutation. JCO Precision Oncology, 2019, 3, 1-8.	1.5	0
50	Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2019, 316, F204-F213.	1.3	6
51	Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Modern Pathology, 2019, 32, 139-146.	2.9	71
52	PD-L1 Antibody Comparison in Urothelial Carcinoma. European Urology, 2019, 75, 538-540.	0.9	40
53	Multi-line fluorescence scanning microscope for multi-focal imaging with unlimited field of view. Biomedical Optics Express, 2019, 10, 6313.	1.5	6
54	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 978-985.	1.3	25

#	Article	IF	Citations
55	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	4.3	14
56	Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Translational Andrology and Urology, 2018, 7, 132-144.	0.6	43
57	Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology, 2018, 73, 983-989.	1.6	24
58	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer, 2018, 18, 8.	1.1	93
59	Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. Oncotarget, 2018, 9, 36444-36456.	0.8	10
60	A Prostate Cancer â€œ Nimbosus â€• Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	0.9	142
61	Primary Cystic Lesions of the Retrorectal Space: MRI Evaluation and Clinical Assessment. American Journal of Roentgenology, 2017, 209, 790-796.	1.0	11
62	EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. International Journal of Molecular Sciences, 2016, 17, 1650.	1.8	6
63	Threeâ€dimensional microscopic analysis of clinical prostate specimens. Histopathology, 2016, 69, 985-992.	1.6	71
64	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
65	Comparison of RNA extraction kits and histological stains for laser capture microdissected prostate tissue. BMC Research Notes, 2016, 9, 17.	0.6	14
66	Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels. Journal of Virology, 2016, 90, 4838-4842.	1.5	107
67	Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential. European Urology, 2016, 69, 710-719.	0.9	25
68	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget, 2016, 7, 70669-70684.	0.8	21
69	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. Oncotarget, 2016, 7, 13167-13181.	0.8	14
70	mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget, 2016, 7, 32916-32924.	0.8	14
71	MET expression during prostate cancer progression. Oncotarget, 2016, 7, 31029-31036.	0.8	18
72	Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget, 2016, 7, 37846-37856.	0.8	14

#	Article	IF	Citations
73	Androgen receptor profiling predicts prostate cancer outcome. EMBO Molecular Medicine, 2015, 7, 1450-1464.	3.3	67
74	Blaaskankerpathologie: van cystoscoop naar microscoop. Tijdschrift Voor Urologie, 2015, 5, 193-198.	0.1	0
75	The role of HOXC6 in prostate cancer development. Prostate, 2015, 75, 1868-1876.	1.2	43
76	Diseaseâ€specific death and metastasis do not occur in patients with Gleason score â‰¤6 at radical prostatectomy. BJU International, 2015, 116, 230-235.	1.3	57
77	Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer. PLoS ONE, 2015, 10, e0126029.	1.1	10
78	Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Modern Pathology, 2015, 28, 457-464.	2.9	239
79	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Modern Pathology, 2015, 28, 695-705.	2.9	37
80	Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. Modern Pathology, 2015, 28, 515-522.	2.9	48
81	Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget, 2015, 6, 4036-4050.	0.8	42
82	Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget, 2015, 6, 24488-24498.	0.8	42
83	Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review. BioMed Research International, 2014, 2014, 1-12.	0.9	41
84	Immunoglobulin G4-related Prostatitis: A Case-control Study Focusing on Clinical andÂPathologic Characteristics. Urology, 2014, 83, 521-527.	0.5	40
85	The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. European Urology, 2014, 66, 1109-1115.	0.9	74
86	Validation of stem cell markers in clinical prostate cancer: Î±6-Integrin is predictive for non-aggressive disease. Prostate, 2014, 74, 488-496.	1.2	37
87	Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. International Journal of Cancer, 2013, 133, 335-345.	2.3	59
88	Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 149-156.	1.4	9
89	Comparison of incidentally detected prostate cancer with screenâ€detected prostate cancer treated by prostatectomy. Prostate, 2012, 72, 108-115.	1.2	22
90	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152

#	Article	IF	Citations
91	A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. Journal of Urology, 2011, 185, 121-125.	0.2	248
92	Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer. PLoS ONE, 2011, 6, e26753.	1.1	66
93	Cysteineâ€rich secretory protein 3 and Î²â€microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome. BJU International, 2011, 108, 1356-1362.	1.3	8
94	No evidence of FGFR3 mutations in prostate cancer. Prostate, 2011, 71, 637-641.	1.2	4
95	Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Modern Pathology, 2011, 24, 1128-1138.	2.9	106
96	The value of EZH2, p27^{kip1}, BMIâ€1 and MIBâ€1 on biopsy specimens with lowâ€risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU International, 2010, 106, 280-286.	1.3	31
97	Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU International, 2009, 104, 321-325.	1.3	23
98	An activating mutation in AKT1 in human prostate cancer. International Journal of Cancer, 2008, 123, 2725-2726.	2.3	17
99	The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU International, 2008, 101, 685-690.	1.3	37
100	Editorial Comment on: Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer. European Urology, 2008, 54, 1323.	0.9	0
101	Polycomb-Group Oncogenes EZH2, BMI1, and RING1 Are Overexpressed in Prostate Cancer With Adverse Pathologic and Clinical Features. European Urology, 2007, 52, 455-463.	0.9	166
102	Despite extensive efforts, the validation of prognostic tissue markers in prostate cancer has not yet resulted in the widespread implementation of novel diagnostic tests. European Urology, 2007, 52, 125.	0.9	1